Top Warren Buffett Stocks To Own For 2019

&l;!–donotpaginate–&g;&l;p&g;When investing, sometimes the best way to make money in the stock market over time is to do nothing. Just invest passively.

That&s;s what &l;a href=&q;https://www.entrepreneur.com/article/306846&q; target=&q;_blank&q;&g;Warren Buffett did in making a $1 million bet&l;/a&g; that he could do better than a portfolio of hedge funds. Did the Oracle of Omaha find some great, bargain-priced stocks? Did he make the deal of the century by finding an emerging tech company?

Nope. He simply said that by investing in a boring, low-cost stock index fund you could outperform most hedge funds over the past decade. He made no new investments and didn&s;t time the 2008 market crash. He just stayed put in an index fund.

How clever is that? Well, it requires no investing skill, although when you do the math, it&s;s brilliant. By just riding the tide of the stock market — and not timing it — you do much better than guessing when to jump in and out. Research proves this works most of the time.

Top Warren Buffett Stocks To Own For 2019: Care.com, Inc.(CRCM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Care.com Inc (NYSE: CRCM) got a boost, shooting up 16 percent to $11.01 after the company reported upbeat quarterly results.

    MaxPoint Interactive Inc (NASDAQ: MXPT) shares were also up, gaining 19 percent to $5.44. MaxPoint Interactive reported Q4 earnings of $0.59 per share on revenue of $46.3 million.

Top Warren Buffett Stocks To Own For 2019: Eagle Bancorp, Inc.(EGBN)

Advisors’ Opinion:

  • [By Paul Ausick]

    Eagle Bancorp Inc. (NASDAQ: EGBN) dropped 28% Friday to post a new 52-week low of $47.65 after closing at $66.15 on Thursday. The stock’s 52-week high is $69.80. Volume of around 3.6 million was more than three times the daily average. The bank holding company had no specific news Friday.

  • [By Lisa Levin]

    On Monday, the financial sector proved to be a source of strength for the market. Leading the sector was strength from Eagle Bancorp, Inc. (NASDAQ: EGBN) and BankUnited (NYSE: BKU).

Top Warren Buffett Stocks To Own For 2019: vTv Therapeutics Inc.(VTVT)

Advisors’ Opinion:

  • [By Stephan Byrd]

    COPYRIGHT VIOLATION NOTICE: “Q1 2018 EPS Estimates for vTv Therapeutics Decreased by Seaport Global Securities (VTVT)” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3350631/q1-2018-eps-estimates-for-vtv-therapeutics-decreased-by-seaport-global-securities-vtvt.html.

  • [By Paul Ausick]

    vTv Therapeutics Inc. (NASDAQ: VTVT) dropped about 79% Tuesday to post a new 52-week low of $0.69. Shares closed at $3.26 on Monday and the stock’s 52-week high is $8.40. Volume was about 30 times the daily average of around 205,000 shares. The company’s Alzheimer drug failed to meet the goals of a phase 3 study.

  • [By Paul Ausick]

    vTv Therapeutics Inc. (NASDAQ: VTVT) dropped about 8.5% Wednesday to post a new 52-week low of $0.65. Shares closed at $0.71 on Tuesday and the stock’s 52-week high is $8.40. Volume was about 7 times the daily average of around 340,000 shares. The company’s Alzheimer drug failed Tuesday to meet the goals of a phase 3 study and the sell-off continues.

Top Warren Buffett Stocks To Own For 2019: Cellectis S.A.(CLLS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Cellectis SA (ADR) (NASDAQ: CLLS) shares dropped 20 percent to $25.70 after announcing FDA clinical hold of UCART123 studies.

    Shares of Opiant Pharmaceuticals Inc (NASDAQ: OPNT) were down 10 percent to $35.20. Opiant Pharma named David O'Toole as CFO.

  • [By Jim Robertson]

    Yesterday, small cap clinical-stage biopharmaceutical stock Cellectis SA (NASDAQ: CLLS) reported that they had received notice fromFDA that a clinical hold was placed on both UCART123 ongoing Phase 1 studies -in acute myeloid leukemia (AML) and in blastic plasmacytoid dendritic cell neoplasm (BPDCN). The clinical hold was initiated after Cellectis reported one fatality in the BPDCN clinical trial (ABC study) with the Company now working closelywith the investigators and the FDA in order to resume the trials with an amended protocol including a lowered dosing of UCART123. The FDA has a detailed page about clinical holds which mentions: